We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
PDS Biotechnology Corporation | NASDAQ:PDSB | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.28 | 8.36% | 3.63 | 3.63 | 3.80 | 3.82 | 3.31 | 3.35 | 675,778 | 00:42:18 |
Delaware
|
26-4231384
|
|
(State or other jurisdiction of incorporation or organization)
|
(I.R.S. Employer Identification No.)
|
Florham Park, NJ
|
07932
|
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
Large Accelerated filer ☐
|
Accelerated filer ☐
|
|
Non-accelerated filer ☒
|
Smaller reporting company ☒
|
|
Emerging growth company ☐
|
Title of securities to be registered(1)
|
Amount to be
registered(2)
|
Proposed
maximum
offering price per
share(3)
|
Proposed
maximum
aggregate offering
price(3)
|
Amount of
registration
fee
|
||||||||||||
Common Stock, par value $0.00033 per share
|
300,000
|
(4)
|
$
|
11.07
|
$
|
3,321,000.00
|
$
|
307.86
|
|
(1) |
The shares registered by PDS Biotechnology Corporation (the “Registrant”) on this Form S-8 Registration represent shares of common stock, par value
$0.00033 per share (“Common Stock”), which are issuable under the PDS Biotechnology Corporation 2019 Inducement Plan, as amended (the “Inducement Plan”).
|
|
(2) |
Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement shall also cover any
additional shares of Common Stock which become issuable under the Inducement Plan by reason of any stock dividend, stock split, recapitalization or other similar transaction effected without the Registrant’s receipt of consideration that
increases the number of the outstanding shares of the Registrant’s Common Stock.
|
|
(3) |
Calculated solely for purposes of this offering under Rule 457(c) and Rule 457(h) of the Securities Act, on the basis of the average of the high and low prices per share of the Registrant’s Common Stock on
November 9, 2021 as reported by the Nasdaq Capital Market.
|
|
(4) |
Represents an increase in the number of shares of Common Stock reserved for issuance under the Inducement Plan, pursuant to an amendment to the Inducement Plan effective as of December 8, 2020.
|
Item 8. |
Exhibits.
|
PDS Biotechnology Corporation
|
||
By:
|
/s/ Frank Bedu-Addo
|
|
Name:
|
Frank Bedu-Addo
|
|
Title:
|
President and Chief Executive Officer
|
Signature
|
Title
|
Date
|
||
/s/ Frank Bedu-Addo |
President, Chief Executive Officer and Director
|
November 15, 2021
|
||
Frank Bedu-Addo
|
(Principal Executive Officer)
|
|||
/s/ Matthew Hill |
Chief Financial Officer
|
November 15, 2021
|
||
Matthew Hill
|
(Principal Financial and Accounting Officer)
|
|||
/s/ Stephen Glover |
Director
|
November 15, 2021
|
||
Stephen Glover
|
||||
/s/ Kamil Ali-Jackson |
Director
|
November 15, 2021
|
||
Kamil Ali-Jackson
|
||||
/s/ Otis W. Brawley |
Director
|
November 15, 2021
|
||
Otis W. Brawley
|
||||
/s/ Gregory Freitag
|
Director
|
November 15, 2021
|
||
Gregory Freitag
|
||||
/s/ Ilian Iliev |
Director
|
November 15, 2021
|
||
Ilian Iliev
|
||||
/s/ Sir Richard Sykes |
Director
|
November 15, 2021
|
||
Sir Richard Sykes
|
1 Year PDS Biotechnology Chart |
1 Month PDS Biotechnology Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions